- Supported exchanges /
- TWO /
- 6535.TWO
Lumosa Therapeutics Co. Ltd. (6535 TWO) stock market data APIs
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Lumosa Therapeutics Co. Ltd. Financial Data Overview
| 317.5 | |
| 323 | |
| - | |
| 329 | |
| 317.5 | |
| 58.9-337 | |
| 52 483 M | |
| 165 M | |
| 47 713 K | |
| -0.71 | |
| 0.37 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Lumosa Therapeutics Co. Ltd. Fundamental Data is available in our Financial Data APIs
- Net Revenue 47 713 K
- EBITDA -335 080 992
- Earnings Per Share -1.74
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Lumosa Therapeutics Co. Ltd. Earnings via APIs
- Latest Release 2024-05-14
- EPS/Forecast -0.61
Get Lumosa Therapeutics Co. Ltd. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
